TP53 and colorectal carcinoma: In patients with RAS mutated CRC, concurrent presence of TP53 mutations conferred significantly reduced overall survival (6.1 months versus 21.1 months, HR 4.2, 95% CI 1.7–10.6, p <0.01) as demonstrated in Fig 2.